Vericel Corp
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns.
Did you know?
Trading 29% above its estimated fair value of $25.84.
Current Price
$36.49
+2.59%GoodMoat Value
$25.84
29.2% overvaluedProfile
Valuation (TTM)
Market Cap$1.85B
P/E111.72
EV—
P/B5.20
Shares Out50.57M
P/Sales6.68
Revenue$276.26M
EV/EBITDA51.69
Vericel Corp (VCEL) Stock Analysis
Market Cap$1.85B
Current Price$36.49
P/E Ratio111.72
Forward P/E—
PEG Ratio7.45
EPS$0.32
Book Value$7.01
P/B Ratio5.20
VCEL Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 4M
Revenue
118M
FY19
124M
FY20
156M
FY21
164M
FY22
198M
FY23
237M
FY24
276M
FY25
Net Income
—
FY19
3M
FY20
—
FY21
—
FY22
—
FY23
10M
FY24
17M
FY25
VCEL 52-Week Range
$29.34
$45.70
50-Day MA: $34.04200-Day MA: $35.68
Did you know?
Trading 29% above its estimated fair value of $25.84.
Vericel Corp (VCEL) Financial Summary
Vericel Corp (VCEL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $36.49 with a market capitalization of $1.85B.
Key valuation metrics include a P/E ratio of 111.72, price-to-book ratio of 5.20, and EPS of $0.32. The company reports a profit margin of 6.0% and return on equity of 4.7%.
VCEL Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $1.85B |
| P/E Ratio | 111.72 |
| EPS | $0.32 |
| P/B Ratio | 5.20 |
| P/S Ratio | 6.68 |
| EV/EBITDA | 51.69 |
| Profit Margin | 6.0% |
| Return on Equity | 4.7% |
| Debt/Equity | 0.27 |
VCEL Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $117.85M | $-9.66M |
| FY20 | $124.18M | $2.86M |
| FY21 | $156.18M | $-7.47M |
| FY22 | $164.37M | $-16.71M |
| FY23 | $197.52M | $-3.18M |
| FY24 | $237.22M | $10.36M |
| FY25 | $276.26M | $16.52M |
Vericel Corp (VCEL) Valuation
Based on GoodMoat's DCF model, Vericel Corp has a fair value estimate of $25.84. At the current price of $36.49, the stock appears 41.2% overvalued relative to our intrinsic value estimate.
VCEL Quality Indicators
Vericel Corp maintains a profit margin of 6.0% and an operating margin of 4.0%. Return on equity stands at 4.7%. The current ratio is 5.03. Debt-to-equity ratio is 0.27.
About Vericel Corp
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns.
VCEL Free Cash Flow
Vericel Corp generated $24.75M in trailing twelve-month free cash flow, representing an FCF yield of 1.34%. This low FCF yield may reflect heavy reinvestment or growth spending.
VCEL Shares Outstanding
Vericel Corp has 0.05 billion shares outstanding at a share price of $36.49, giving it a market capitalization of $1.85B.